Balkanpharma Troyan AD
Balkanpharma Troyan AD, a prominent player in the pharmaceutical industry, is headquartered in Troyan, Bulgaria (BG). Established in 1997, the company has made significant strides in the production of high-quality generic medicines and active pharmaceutical ingredients (APIs). With a strong focus on research and development, Balkanpharma has carved a niche in therapeutic areas such as cardiology, psychiatry, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that meet stringent international standards. Balkanpharma's strategic position in the Balkan region and beyond has enabled it to achieve notable milestones, including various certifications and partnerships that enhance its market presence. As a trusted name in pharmaceuticals, Balkanpharma Troyan AD continues to contribute to healthcare advancements while maintaining a strong reputation for reliability and excellence.
DitchCarbon Score
How does Balkanpharma Troyan AD's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Balkanpharma Troyan AD's score of 26 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Balkanpharma Troyan AD's reported carbon emissions
Balkanpharma Troyan AD, headquartered in Bulgaria (BG), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to adopt science-based targets to mitigate their environmental impact. As such, it is essential for Balkanpharma Troyan AD to consider establishing clear emissions reduction goals and strategies to align with industry standards and contribute to global climate efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Balkanpharma Troyan AD is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
